Teclistamab, which targets CD3 and BCMA and is used in relapsed or refractory multiple myeloma [70], has demonstrated promise in treating refractory autoimmune diseases, including systemic sclerosis, Sjögren’s syndrome, and rheumatoid arthritis (RA) [68]. The gene discussed is TNFRSF17; the disease is autoimmune disease.